Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vichitra Behel
Institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital
Observed institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital
ORCID:
0000-0001-6522-6033
Observed ORCID:
0000-0001-6522-6033
OpenAlex ID:
A5016040141
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer
2019
·
Vanita Noronha
, Vijay Maruti Patil
, et al.
·
Journal of Clinical Oncology
·
456
Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
2022
·
Vichitra Behel
, Vanita Noronha
, et al.
·
JCO Global Oncology
·
29
Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).
2019
·
Vanita Noronha
, Amit Joshi
, et al.
·
Journal of Clinical Oncology
·
29
Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC
2022
·
Vichitra Behel
, Anuradha Chougule
, et al.
·
Clinical Lung Cancer
·
15
Catch-22: COVID versus Cancer
2020
·
Vanita Noronha
, Vichitra Behel
·
Cancer Research Statistics and Treatment
·
15
The efficacy and safety of first-line therapy for the epidermal growth factor receptor mutant non-small cell lung cancer in older versus younger patients: A pooled analysis of two randomized controlled trials
2020
·
Vanita Noronha
, Akhil Kapoor
, et al.
·
Cancer Research Statistics and Treatment
·
11
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
2019
·
Vijay Patil
, Vanita Noronha
, et al.
·
EClinicalMedicine
·
11
PDF
Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations
2022
·
Vichitra Behel
, Vanita Noronha
, et al.
·
Cancer Research Statistics and Treatment
·
8
Concordance of epidermal growth factor receptor mutation detection in bodily fluids other than blood with tissue biopsy: A retrospective analysis
2020
·
Anuradha Chougule
, Priyanka Pange
, et al.
·
Cancer Research Statistics and Treatment
·
7
Authors' reply to Vora et al. and Singh et al.
2020
·
Vanita Noronha
, Akhil Kapoor
, et al.
·
Cancer Research Statistics and Treatment
·
1
Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing
2025
·
Vichitra Behel
, Supriya Hait
, et al.
·
npj Systems Biology and Applications
PDF
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.
2024
·
Kumar Prabhash
, Atul Bharde
, et al.
·
Journal of Clinical Oncology
Comprehensive plasma genotyping of patients with EGFR positive NSCLC as a monitoring tool for therapy response and disease progression.
2023
·
Gowhar Shafi
, Vichitra Behel
, et al.
·
Journal of Clinical Oncology
Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.
2023
·
Atul Bharde
, Vichitra Behel
, et al.
·
Journal of Clinical Oncology
PDF
Authors’ reply to Sahoo, and Bharath and Malik
2022
·
Vichitra Behel
, Vanita Noronha
, et al.
·
Cancer Research Statistics and Treatment
Show more works
View as search
Works count:
15
Citation count:
582
H-index:
8
I10-index:
7
Year
Topic
Type